Ondansetron: A review of its pharmacology and preliminary clinical findings in novel applications

Drugs

Volumn 52, Issue 5, 1996, Pages 773-794

  Wilde, Michelle I ^a   Markham, Anthony ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ANTIDEPRESSANT AGENT; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; COTRIMOXAZOLE; DAPSONE; FLUVOXAMINE; HALOPERIDOL; METOCLOPRAMIDE; ONDANSETRON; SEROTONIN 3 RECEPTOR; TRIMETHOPRIM;

ALCOHOLISM; ANAPHYLAXIS; ANESTHESIA; CANCER RADIOTHERAPY; CANCER SURGERY; CARCINOID SYNDROME; CLINICAL TRIAL; CONSTIPATION; CRYPTOSPORIDIOSIS; DEMENTIA; DIABETES MELLITUS; DIARRHEA; DROWSINESS; DRUG INTOXICATION; DRUG OVERDOSE; DRUG RECEPTOR BINDING; EXTRAPYRAMIDAL SYNDROME; GASTROINTESTINAL MOTILITY; HEADACHE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; IRRITABLE COLON; NAUSEA; NEUROLOGIC DISEASE; NONHUMAN; ORAL DRUG ADMINISTRATION; PAIN; PARKINSON DISEASE; PRURITUS; REVIEW; SEIZURE; TREMOR; UREMIA; VERTIGO; VOMITING; WITHDRAWAL SYNDROME;

EID: 0029847458     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199652050-00010     Document Type: Review

References (185)

1. Kim H, Rosenberg SA, Steinberg SM, et al. A randomized double-blinded comparison of the antiemetic efficacy of ondansetron and droperidol in patients receiving high-dose interleukin-2. J Immunother Emphasis Tumor Immunol 1994 Jul; 16: 60-5
2. Naguib M, Bakry AK, Khoshim MHB, et al. Prophylactic anti-emetic therapy with ondansetron, tropisetron, granisetron and metoclopramide in patients undergoing laparoscopic cholecystectomy: a randomized, double-blind comparison with placebo. Can J Anaesth 1996 Mar; 43: 226-31
3. Markham A, Sorkin EM. Ondansetron: an update of its therapeutic use in chemotherapy-induced and postoperative nausea and vomiting. Drugs 1993 Jun; 45: 931-52
4. Paxton LD, McKay AC, Mirakhur RK. Prevention of nausea and vomiting after day case gynaecological laparoscopy: a comparison of ondansetron, droperidol, metoclopramide and placebo. Anaesthesia 1995 May; 50: 403-6
5. Joslyn AF. Ondansetron, clinical development for postoperative nausea and vomiting: current studies and future directions. Anaesthesia 1994 Jan; 49 Suppl.: 34-7
6. 3 receptor agents. Pharmacol Rev 1991 Dec; 43: 579-86
7. 3 receptors: pharmacologic and therapeutic aspects. J Clin Pharmacol 1995 Sep; 35: 845-55
8. 3 antagonists: recent advances. Prog Med Chem 1992; 29: 239-70
9. 3 receptors in drug dependence. Drug Alcohol Depend 1995; 38: 155-71
10. 3 antagonists. New generation antiemetics. Curr Ther 1993 Jul; 34: 15-8
11. Tyers MB. Pharmacology and preclinical antiemetic properties of ondansetron. Semin Oncol 1992 Aug; 19 Suppl. 10: 1-8
12. Naylor RJ, Rudd JA. Pharmacology of ondansetron. Eur J Anaesthesiol 1992 Nov; 9 Suppl. 6: 3-10
13. 4 receptors of the release of 5-hydroxytryptamine from the guinea-pig small intestine. Naunyn Schmiedebergs Arch Pharmacol 1993; 347: 137-40
14. Costall B, Naylor RJ. Serotonin and psychiatric disorders A key to new therapeutic approaches. Arzneimittel Forschung 1992 Feb; 42: 246-9
15. 3-receptor antagonist. Am J Med Sci 1992 Dec; 304: 373-8
16. 3 receptors in gastric function and ethanol- induced mucosal damage in rat stomachs. Pharmacology 1994 Sep; 49: 137-43
17. Kaneko H, Mitsuma T, Morise K, et al. Effect of serotonin on the immunoreactive thyrotropin-releasing hormone concentrations of the rat stomach. Digestion 1992; 53: 149-56
18. 3 antagonist, on copper sulfate-induced emesis in the ferret. Biog Amines 1991; 8 (2): 79-86
19. 3 receptors. Eur J Pharmacol 1995 May 26; 293: 71-6
20. Martelletti P, Stirparo G, Rinaldi C, et al. Upregulated expression of peripheral serotonergic receptors in migraine and cluster headache by sumatriptan. Int J Clin Pharmacol Res 1994; 14 (5-6): 165-75
21. Yoshioka M, Ikeda T, Abe M, et al. Effect of 5-hydroxytryptamine on external carotid nerve activity and its blockade by GR38032F in anesthetized rats. Res Commun Chem Pathol Pharmacol 1991 Oct; 74: 39-45
22. 3 receptors and cerebral dopamine function: implications for the treatment of schizophrenia and psychoactive substance abuse. Psychopharmacology 1993; 112 Suppl.: 68-75
23. 3 receptor antagonist, ondansetron, on brain stimulation reward, and its interaction with direct and indirect stimulants of central dopaminergic transmission. J Neural Transm Gen Sect 1993; 91 (1): 1-11
24. 3H]-acetylcholine release in the guinea-pig ileum. Br J Pharmacol 1990 Nov; 101: 553-6
25. Matsumoto M, Yoshioka M, Togashi H, et al. Modulation of norepinephrine release by serotonergic receptors in the rat hippocampus as measured by in vivo microdialysis. J Pharmacol Exp Ther 1995 Mar; 272: 1044-51
26. 3H]noradrenaline in rat brain limbic structures. Eur J Pharmacol 1994 May 2; 256: 269-79
27. 3-antagonist, ondansetron, inhibits GH secretion in healthy volunteers and patients with obsessive-compulsive disorder [abstract]. Neuropsychopharmacology 1994 May; 10 Suppl. Pt 2: 151
28. 3 receptors in the secretion of prolactin, ACTH and renin. Neuroendocrinology 1993 Jul; 58: 65-70
29. 3 receptor antagonists on the prolactin response to restraint and ether stress. Neuroendocrinology 1992 Sep; 56: 371-7
30. Ulrich U, Nowara I, Rossmanith WG. Serotoninergic control of gonadotrophin and prolactin secretion in women. Clin Endocrinol Oxf 1994 Dec; 41: 779-85
31. 3 receptor antagonists. Int Clin Psychopharmacol 1993 Nov; 8 Suppl. 2: 3-9
32. 3 receptor antagonists. YM060 YM114 (KAE-393), granisetron and ondansetron in rat vagus nerve and cerebral cortex. Neuropharmacology 1995 Jun; 34: 631-7
33. Koch KL, Xu L, Bingaman S, et al. Effects of ondansetron on morphine-induced nausea, vasopressin and gastric myoelectrical activity in healthy humans [abstract]. Gastroenterology 1993 Apr; 104 Suppl.: A535
34. 3 receptor antagonists on alcohol drinking in rats. Alcohol 1995 Jul-Aug; 12: 387-91
35. Costall B, Jones BJ, Kelly ME, et al. Sites of action of ondansetron to inhibit withdrawal from drugs of abuse. Pharmacol Biochem Behav 1990 May; 36: 97-104
36. Forster ER, Dockray GJ. The effect of ondansetron on gastric emptying in the conscious rat. Eur J Pharmacol 1990 Nov 27; 191: 235-8
37. 3-receptor antagonist on gastric emptying in the guinea-pig. Br J Pharmacol 1987; 91: 263-4
38. 3-receptor blockade protects against gastric mucosal damage in rats. Acta Physiol Hung 1992; 80: 181-8
39. Qiu BS, Hui S-CG, Wong D, et al. A study on the influence of peripheral or central administration of ondansetron on stress-induced gastric ulceration [abstract]. Can J Physiol Pharmacol 1994; 72 Suppl. 1: 240
40. Ogle CW, Hui S-CG. The influence of peripheral or central administration of ondansetron on stress-induced gastric ulceration in rats. Experientia 1995 Aug 16; 51: 786-9
41. 3 receptor antagonists in visceromotor and nociceptive responses to rectal distension before and during experimental colitis in rats. Fundam Clin Pharmacol 1994; 8: 553-62
42. Moss HE, Sanger GJ. The effects of granisetron, ICS 205-930 and ondansetron on the visceral pain reflex induced by duodenal distension. Br J Pharmacol 1990 Jul; 100: 497-501
43. 3 receptor antagonist ondansetron on intestinal obstruction in the rat [abstract]. Acta Physiol Scand 1992; 146 Suppl. 608: 61
44. Sommers DK, van WM, Snyman JR, et al. Influence of granisetron, ondansetron and metoclopramide on gastric emptying, oro-caecal transit time and theophylline absorption from a sustained-release formulation. Med Sci Res 1994 May 1-31; 22: 329-31
45. Van Wyk M, Sommers D-K, Snyman JR, et al. The effect of metoclopramide, ondansetron, and granisetron on liquid gastric emptying in normal subjects. Curr Ther Res 1995; 56 (6): 581-6
46. Gore S, Gilmore IT, Haigh CG, et al. Colonic transit in man is slowed by ondansetron (GR38032F), a selective 5-hydroxytryptamine receptor (type 3) antagonist. Aliment Pharmacol Ther 1990 Apr; 4: 139-44
47. 3-receptor antagonist, on perception of gastric distension and gastric compliance in healthy man [abstract]. Gastroenterology 1993 Apr; 104 Suppl.: A603
48. Fiorucci S, Santucci L, Morelli A. 5-Hydroxytryptamine 3-receptor antagonist modulates gallbladder emptying and motilin release induced by erythromycin. Dig Dis Sci 1993 Dec; 38: 2236-40
49. 3 receptor antagonist, slows colonic transit in healthy man. Dig Dis Sci 1990 Apr; 35: 477-80
50. von der Ohe MR, Hanson RB, Camilleri M. Serotonergic mediation of postprandial colonic tonic and phasic responses in humans. Gut 1994 Apr; 35: 536-41
51. Scolapio JS, Camilleri M, von der Ohe MR, et al. Ascending colon response to feeding: evidence for a 5-hydroxytryptamine-3 mechanism. Scand J Gastroenterol 1995 Jun; 30: 562-7
52. 3 antagonist (GR 38032F) on small intestinal transit release of gastrointestinal peptides. Dig Dis Sci 1989 Oct; 34: 1511-5
53. 3 receptor antagonist, on duodenal motility in man [abstract]. Gastroenterology 1992 Apr; 102 (Pt 2): A534
54. Brown NJ, Horton A, Rumsey RDE, et al. The influence of ondansetron & granisetron on the gastrointestinal response to ileal lipid infusion [abstract]. J Gastrointest Motil 1992 Sep; 4: 212
55. Allescher HD, Willis S, Stoschus B, et al. Effect of molsidomin and ondansetron on human esophageal motility [abstract]. J Gastrointest Motil 1993 Sep; 5: 178
56. 3 receptor antagonist, on cognition in rodents and primates. Pharmacol Biochem Behav 1990 Apr; 35: 955-62
57. Carey GJ, Costall B, Domeney AM, et al. Ondansetron and arecoline prevent scopolamine-induced cognitive deficits in the marmoset. Pharmacol Biochem Behav 1992 May; 42: 75-83
58. Domeney AM, Costall B, Gerrard PA, et al. The effect of ondansetron on cognitive performance in the marmoset. Pharmacol Biochem Behav 1991 Jan; 38: 169-75
59. Fontana DJ, Daniels SE, Henderson C, et al. Ondansetron improves cognitive performance in the Morris water maze spatial navigation task. Psychopharmacology 1995 Aug; 120(4): 409-17
60. 3 receptor antagonists WAY-100579 and ondansetron on spatial learning in the water maze in rats with excitotoxic lesions of the forebrain cholinergic projection system. Psychopharmacology 1996; 125: 146-61
61. Little JT, Broocks A, Martin A, et al. Serotonergic modulation of anticholinergic effects on cognition and behavior in elderly humans. Psychopharmacology 1995 Aug; 120 (3): 280-8
62. Broocks A, Little JT, Martin A, et al. The effect of ondansetron and m-CPP on scopolamine-induced cognitive and behavioral changes in young healthy volunteers [abstract]. Pharmacopsychiatry 1995 Sep; 28: 168
63. Meert TF. Effects of various serotonergic agents on alcohol intake and alcohol preference in Wistar rats selected at two different levels of alcohol preference. Alcohol Alcohol 1993 Mar; 28: 157-70
64. Tomkins DM, Le AD, Sellers EM. Effect of the 5-HT3 antagonist ondansetron on voluntary ethanol intake in rats and mice maintained on a limited access procedure. Psychopharmacology 1995 Feb; 117 (4): 479-85
65. 3 antagonists fail to affect ethanol self-administration of rats. Alcohol 1994 Sep-Oct; 11: 389-95
66. Kostowski W, Bisaga A, Jankowska E, et al. Studies on the effects of certain 5-HT-3 receptor antagonists on ethanol preference and withdrawal seizures in the rat. Pol J Pharmacol 1994 May-Jun; 46: 133-7
67. Higgins GA, Tomkins DM, Fletcher PJ, et al. Effect of drugs influencing 5-HT function on ethanol drinking and feeding behaviour in rats: studies using a drinkometer system. Neurosci Biobehav Rev 1992; 16: 535-52
68. Svensson L, Fahlke C, Hard E, et al. Involvement of the serotonergic system in ethanol intake in the rat. Alcohol 1993; 10: 219-24
69. Costall B, Jones BJ, Kelly ME, et al. Ondansetron inhibits a behavioural consequence of withdrawing from drugs of abuse. Pharmacol Biochem Bchav 1990 Jun; 36: 339-44
70. Vanhaaren F. Effects of cocaine alone and in combination with prazosin orondansetron on multiple fixed-interval fixed-ratio performance in pigeons. Pharmacol Biochem Behav 1992 Aug; 42: 849-53
71. 3 receptor modulation of behavior during withdrawal from continuous or intermittent cocaine. Pharmacol Biochem Behav 1994 Mar; 47: 399-407
72. Depoortere RY, Li DH, Lane JD, et al. Parameters of self-administration of cocaine in rats under a progressive-ratio schedule. Pharmacol Biochem Behav 1993 Jul; 45: 539-48
73. 3 antagonist, fails to alter cocaine self-administration in rats. Pharmacol Biochem Behav 1991 May; 39: 133-6
74. 3 receptor antagonists and the indirect 5-HT agonist, dexfenfluramine, on heroin self-administration in rats. Psychopharmacology Berl 1994 May; 114: 611-9
75. Lane JD, Pickering CL, Hooper ML, et al. Failure of ondansetron to block the discriminative or reinforcing stimulus effects of cocaine in the rat. Drug Alcohol Depend 1992 Jun; 30: 151-62
76. 3 receptor antagonists on the discriminative stimulus properties of morphine in rats. Psychopharmacology 1993 Aug; 112: 111-5
77. 3 receptor antagonists do not block nicotine induced hyperactivity in rats. Psychopharmacology 1995 May; 119: 213-21
78. Doty P, Zacny JP, de Wit H. Effects of ondansetron pretreatment on acute responses to ethanol in social drinkers. Behav Pharmacol 1994 Aug; 5: 461-9
79. 3 receptor blockade: a preliminary study in healthy male volunteers. Psychopharmacology 1993 Aug; 112: 142-4
80. 3 receptor antagonists inhibit morphine-induced stimulation of mesolimbic dopamine release and function in the rat. Eur J Pharmacol 1993 Jan 5; 230: 63-8
81. 3 receptor [abstract]. J Clin Pharmacol 1991 Mar; 31: 268
82. Warburton EC, Joseph MH, Feldon J, et al. Antagonism of amphetamine-induced disruption of latent inhibition in rats by haloperidol and ondansetron: implications for a possible antipsychotic action of ondansetron. Psychopharmacology 1994 May; 114: 657-64
83. 3 receptor antagonist, on dopamine and serotonin metabolism in mesolimbic and nigrostriatal dopaminergic neurons. Eur J Pharmacol 1989 Oct 10; 169: 321-4
84. 3 receptor antagonist, on monoamine metabolism in mesolimbic and nigrostriatal dopaminergic neurons and on striatal D2-receptor binding. Psychopharmacology 1990; 101 (2): 168-71
85. 3 receptor antagonist, partially attenuates the effects of amphetamine: a pilot study in healthy volunteers. Int Clin Psychopharmacol 1992; 7 (1): 37-43
86. Handley SL, McBlane JW. 5HT drugs in animal models of anxiety. Psychopharmacology 1993 Aug; 112: 13-20
87. 3 receptor antagonists, ondansetron and WAY 100289, in the elevated plus-maze test of anxiety of mice. Psychopharmacology 1995 Feb; 117 (3): 306-12
88. Stefanski R, Palejko W, Koslowski W, et al. The comparison of benzodiazepine derivatives and serotonergic agonists and antagonists in 2 animal models of anxiety. Neuropharmacology 1992 Dec; 31: 1251-8
89. 3 receptor antagonists. Neuropharmacology 1993 Oct; 32: 987-93
90. 3 receptor can reduce the fear-potentiated startle response in the rat: evidence for different types of anxiolytic activity? J Pharmacol Exp Ther 1994 Jan; 268: 248-54
91. 3 antagonists ondansetron, zacopride. 3α-tropanyl-1H-indole-3-carboxylic acid ester, and 1αH, 3α, 5-αH-tropan-3-yl-3,5-dichlorobenzoate. Drug Dev Res 1991; 23 (4): 289-300
92. 3 receptor antagonists at inhibiting aversive behavior to illumination and the von Bezold-Jarisch reflex in the mouse. Neuropharmacology 1994 Feb; 33: 227-34
93. Castejon AM, Aquino R, Cubeddu LX. Comparative effects of diazepam, chlordiazepoxide, buspirone and ondansetron in punished and unpunished responding in pigeons [abstract]. Can J Physiol Pharmacol 1994; 72 Suppl. 1: 363
94. 3 antagonist GR38032F (ondansetron) on benzodiazepine withdrawal in rats. Eur J Pharmacol 1990 Aug 28; 185: 179-86
95. Costall B, Jones BJ, Kelly ME, et al. The effects of ondansetron (GR38032F) in rats and mice treated subchronically with diazepam. Pharmacol Biochem Behav 1989 Dec; 34: 769-78
96. Valdman EA, Garibova TL, Kalinina TS, et al. Effects of ondansetron and buspirone in benzodiazepine withdrawal syndrome. Behav Pharmacol 1996; 7 Suppl. 1: 114
97. Mizoguchi H, Shirayama N, Tsuda M, et al. Potentiation of physical dependence on diazepam by ondansetron in rats. Life Sci 1994; 54 (9): PL131-6
98. Mizoguchi H, Suzuki T, Misawa M. Effects of serotonergic anxiolytics on physical dependence on diazepam in mice. Neurosci Lett 1993 Sep 17; 160: 41-4
99. 3 antagonist ondansetron on benzodiazepine-induced operant behavioural dependence in rats. Psychopharmacology 1992 Dec; 109: 461-5
100. Prather PL, Rezazadeh SM, Lane JD, et al. Conflicting evidence regarding the efficacy of ondansetron in benzodiazepine withdrawal. J Pharmacol Exp Ther 1993 Feb; 264: 622-30
101. O'Hanlon JF, Vermeeren A, Uiterwijk MMC, et al. Anxiolytics' effects on the actual driving performance of patients and healthy volunteers in a standardized test: an integration of three studies. Neuropsychobiology 1995; 31 (2): 81-8
102. van Veggel LMA, Preston C, O'Hanlon JF. Ondansetron and diazepam effects on actual driving and psychomotor performance. [abstract]. Neuropsychopharmacology 1994; 10 (3S Pt 2): 27S.
103. Hall ST, Ceuppens PR. A study to evaluate the effect of ondansetron on psychomotor performance after repeated oral dosing in healthy subjects. Psychopharmacology 1991; 104 (1): 86-90
104. 3 receptor antagonists reverse helpless behaviour in rats. Eur J Pharmacol 1992 Feb 23; 212: 73-8
105. Roila F, Del Favero A. Ondansetron clinical pharmacokinetics. Clin Pharmacokinet 1995 Aug; 29: 95-109
106. Spahr-Schopter IA, Lerman J, Sikich N, et al. Pharmacokinetics of intravenous ondansetron in healthy children undergoing ear, nose, and throat surgery. Clin Pharmacol Ther 1995 Sep; 58: 316-21
107. Bozigian HP, Pritchard JF, Gooding AE, et al. Ondansetron absorption in adults: effect of dosage form, food, and antacids. J Pharm Sci 1994; 83 (7): 1011-3
108. Hsyu P-H, Pritchard JF, Bozigian HP, et al. Comparison of the pharmacokinetics of an ondansetron solution (8 mg) when administered intravenously, orally, to the colon, and to the rectum. Pharm Res 1994 Jan; 11: 156-9
109. Simpson KH, Murphy P, Colthup PV, et al. Concentration of ondansetron in cerebrospinal fluid following oral dosing in volunteers. Psychopharmacology 1992 Dec; 109: 497-8
110. Pritchard JF. Ondansetron metabolism and pharmacokinetics. Semin Oncol 1992; 19 Suppl. 10: 9-15
111. Dixon CM, Colthup PV, Serabjit-Singh CJ, et al. Multiple forms of cytochrome P450 are involved in the metabolism of ondansetron in humans. Drug Metab Dispos 1995 Nov; 23: 1225-30
112. Fischer V, Vickers AEM, Heitz F, et al. The polymorphic cytochrome P-4502D6 is involved in the metabolism of both 5-hydroxytryptamine antagonists, tropisetron and ondansetron. Drug Metab Dispos 1994 Mar-Apr; 22: 269-74
113. Ashforth EIL, Palmer JL, Bye A, et al. The pharmacokinetics of ondansetron after intravenous injection in healthy volunteers phenotyped as poor or extensive metabolisers of debrisoquine. Br J Clin Pharmacol 1994 Apr; 37: 389-91
114. Blake JC, Palmer JL, Minton NA, et al. The pharmacokinetics of intravenous ondansetron in patients with hepatic impairment. Br J Clin Pharmacol 1993 Apr; 35: 441-3
115. Figg WD, Dukes GE, Pritchard JF, et al. Pharmacokinetics of ondansetron in patients with hepatic insufficiency. J Clin Pharmacol 1996 Mar; 36: 206-15
116. Colthup PV, Felgate CC, Palmer JL, et al. Determination of ondansetron in plasma and its pharmacokinetics in the young and elderly. J Pharm Sci 1991 Sep; 80: 868-71
117. Pritchard JF, Bryson JC, Kernodle AE, et al. Age and gender effects on ondansetron pharmacokinetics: evaluation of healthy aged volunteers. Clin Pharmacol Ther 1992; 51: 51-5
118. Kennard D, Butcher M, Palmer J, et al. The anti-emetic efficacy, pharmacokinetics and safety of ondansetron in the elderly receiving cancer chemotherapy or radiotherapy. Eur J Cancer 1991; 27: S27
119. Sage TA, Jones WN, Clark RF. Ondansetron in the treatment of intractable nausea associated with theophylline toxicity. Ann Pharmacother 1993 May; 27: 584-5
120. Daly D, Taylor JN. Ondansetron in theophylline overdose. Anaesth Intensive Care 1993 Aug; 21: 474-5
121. Roberts JR, Carney S, Boyle SM, et al. Ondansetron quells drug-resistant emesis in theophylline poisoning. Am J Emerg Med 1993 Nov; 11: 609-10
122. Brown SGA, Prentice DA. Ondansetron in the treatment of theophylline overdose. Med J Aust 1992 Apr 6; 156: 512
123. Clark RF, Chen R, Williams SR, et al. The use of ondansetron in the treatment of nausea and vomiting associated with acetaminophen poisoning. J Toxicol Clin Toxicol 1996 Mar; 34: 163-7
124. Tobias JD, Gregory DF, Deshpande JK. Ondansetron to prevent emesis following N-acetylcysteine for acetaminophen intoxication. Pediatr Emerg Care 1992 Dec; 8: 345-6
125. Reed MD, Marx CM. Ondansetron for treating nausea and vomiting in the poisoned patient. Ann Pharmacother 1994 Mar; 28: 331-3
126. Dones I, Servello D, Ferrazza C, et al. Ondansentron as a treatment of intrathecal baclofen overdosage: a case report. J Neurology 1995; 242 Suppl. 2: 94
127. Compels M, McWilliams S, Ohare M, et al. Ondansetron usage in HIV positive patients: a pilot study on the control of nausea and vomiting in patients on high dose co-trimoxazole for Pneumocystis-Carinii pneumonia. Int J STD AIDS 1993 Sep-Oct; 4: 293-6
128. 3 antagonist? [abstract]. Neuropsychopharmacology 1994 May; 10 Suppl. Pt 2: 220
129. Sullivan CA, Johnson CA, Roach H, et al. A pilot study of intravenous ondansetron for hyperemesis gravidarum. Am J Obstet Gynecol 1996; 174: 1565-8
130. Guikontes E, Spantideas A, Diakakis J. Ondansetron and hyperemesis gravidarum. Lancet 1992 Nov 14; 340: 1223
131. Andrews PA, Quan V, Ogg CS. Ondansetron for symptomatic relief in terminal uraemia. Nephrol Dial Transplant 1995; 10 (1): 140
132. Andrews PA. Use of ondansetron, a new antiemetic, in uremia. Semin Dialysis 1995 Jul-Aug; 8: 245-6
133. Kleinerman KB, Deppe SA, Sargent AI. Use of ondansetron for control of projectile vomiting in patients with neurosurgical trauma: two case reports. Ann Pharmacother 1993 May; 27: 566-8
134. Abell TL, Werkman R, Voeller G, et al. Long-term therapy with ondansetron is effective in patients with refractory nausea and vomiting [abstract]. Gastroenterology 1995 Apr; 108 Suppl.: 1
135. Tobias JD. Ondansetron: indications and applications in the paediatric intensive care unit. Anaesth Intensive Care 1992 Nov; 20: 504-6
136. 3 antagonist corrects the postprandial colonic hypertonic response in carcinoid diarrhea. Gastroenterology 1994 May; 106: 1184-9
137. Leijsma JK, Kleibeuker JH, Sleijfer DT, et al. Effects of ondansetron on symptoms and gastric emptying in carcinoid patients [abstract]. Proc Am Soc Clin Oncol 1994 Mar; 13: 190
138. Schwörer H, Münke H, Stöckmann F, et al. Treatment of diarrhea in carcinoid syndrome with ondansetron, tropisetron, and clonidine. Am J Gastroenterol 1995 Apr; 90: 645-8
139. Platt AJ, Heddle RM, Rake MO, et al. Ondansetron in carcinoid syndrome. Lancet 1992 Jun 6; 339: 1416
140. Steadman CJ, Talley NJ, Phillips SF, et al. Selective 5-hydroxytryptamine type 3 receptor antagonism with ondansetron as treatment for diarrhea-predominant irritable bowel syndrome: a pilot study. Mayo Clin Proc 1992 Aug; 67: 732-8
141. Maxton DG, Morris J, Whorwell PJ. Selective 5-hydroxytryptamine antagonism: a role in irritable bowel syndrome and functional dyspepsia. Aliment Pharmacol Ther 1996; 10: 595-9
142. 3-antagonist (ondansetron) on rectal sensitivity and compliance in health and the irritable bowel syndrome. Aliment Pharmacol Ther 1993 Oct; 7: 543-51
143. 3 antagonism (ondansetron) does not modify visceral sensation, bowel compliance or symptoms in healthy subjects or irritable bowel patients [abstract]. Gut 1993; 34 (4) Suppl.: 55
144. Schwörer H, Hartmann H, Ramadori G. Treatment of chronic cryptosporidiosis-induced diarrhea with a serotonin receptor antagonist. Am J Gastroenterol 1994 Mar; 89: 458
145. Nielsen OH, Hvid-Jacobsen K, Lund P, et al. Gastric emptying and subjective symptoms of nausea: lack of effects of a 5-hydroxytryptamine-3 antagonist ondansetron on gastric emptying in patients with gastric stasis syndrome. Digestion 1990 Jun; 46: 89-96
146. Bossi A, Baresi A, Ballini A, et al. Ondansetron in the treatment of diabetic diarrhea. Diabetes Care 1994 May; 17: 453-4
147. Evans JE. Nausea, abdominal pain and diarrhoea of uncertain cause responding to ondansetron. Med J Aust 1993 Jul 19; 159: 125-7
148. Schwörer H, Ramadori G Treatment of pruritus: a new indication for serotonin type 3 receptor antagonists. Clin Investig 1993 Aug; 71: 659-62
149. Raderer M, Müller C, Scheithauer W. Ondansetron for pruritus due of cholestasis. N Engl J Med 1994 May 26; 330: 1540
150. 3) receptor antagonists: effectiveness of ondansetron. Pain 1995 Apr; 61: 33-7
151. Crighton IM, Hobbs GJ, Reid MF. Ondansetron for the treatment of pruritis after spinal opioids. Anaesthesia 1996 Feb; 51: 199-200
152. Schwörer H, Ramadori G. Treatment of acute gouty arthritis with the 5-hydroxytryptamine antagonist ondansetron. Clin Investig 1994 Oct; 72: 811-3
153. Hrycaj P, Stratz T, Mennet P, et al. Pathogenetic aspects of responsiveness to ondansetron (5-hydroxytryptamine type 3 receptor antagonist) in patients with primary fibromyalgia syndrome - a preliminary study. J Rheumatol 1996; 23: 1418-23
154. Stratz T, Schochat T, Hrycaj P, et al. Therapy of fibromyalgia by blocking of S3 receptors [in German]. Z Rheumatol 1994 Nov-Dec; 53: 335-8
155. 3 antagonist ondansetron in alcohol abuse and dependence. Alcohol Clin Exp Res 1994 Aug; 18: 879-85
156. Loimer N, Hofmann P, Chaudhry H. Ultrashort noninvasive opiate detoxification [letter]. Am J Psychiatry 1993 May; 150: 839
157. Sell LA, Cowen PJ, Robson PJ. Ondansetron and opiate craving: a novel pharmacological approach to addiction. Br J Psychiatry 1995 Apr; 166: 511-4
158. Rice GPA, Ebers GC. Ondansetron for intractable vertigo complicating acute brainstem disorders. Lancet 1995 May 6; 345: 1182-3
159. Rice G, Dickey C, Lesaux J, et al. Ondansetron for disabling cerebellar tremor [abstract]. Ann Neurol 1995 Dec; 38: 973
160. Zoldan J, Friedberg G, Weizman A, et al. Zofran Rm (ondansetron), a 5-HT3 receptor antagonist: administration in 16 patients with Parkinson's disease and levodopa-associated psychosis [abstract]. Neurology 1994 Apr; 44 Suppl. 2: 254
161. Zoldan J, Friedberg G, Weizman A, et al. Psychosis in levodopa-treated Parkinsonian patients: clinical features and response to ondansetron, a selective 5-HT3 antagonist [abstract]. Neurology 1995 Apr; 45 Suppl. 4: 167
162. López del Val LJ, Jericó Pascual I, López del Val JA. Treatment of hallucinations with ondansetron in 23 patients with advanced Parkinson's disease. Mov Disord 1996; 11 Suppl. 1: 193
163. Zoldan J, Friedberg G, Weizman A, et al. Recurrent acute psychosis following repeated trials of levodopa initiation in de novo patients with Parkinson's disease: reversal of intolerance by preparatory pretreatment with ondansetron, a 5-HT3 antagonist [abstract]. Mov Disord 1995 Sep; 10: 694
164. White A, Corn TH, Feetham C, et al, Ondansetron in treatment of schizophrenia. Lancet 1991 May 11; 337: 1173
165. Mathew RJ, Wilson WH. Evaluation of the effects of diazepam and an experimental anti-anxiety drug on regional cerebral blood flow. Psychiatry Res Neuroimaging 1991 Oct; 40: 125-34
166. Plosker GL, Milne RJ. Ondansetron: a pharmacoeconomic and quality-of-life evaluation of its antiemetic activity in patients receiving cancer chemotherapy. PharmacoEconomics 1992; 2 (4): 285-304
167. Krstenansky PM, Petree J, Long G. Extrapyramidal reaction caused by ondansetron [letter]. Ann Pharmacother 1994 Feb; 28: 280
168. Camp-Sorrell D. Managing an extrapyramidal reaction caused by ondansetron. Oncol Nurs Forum 1995 May; 22: 718-9
169. Mathews IIIHG, Tancil CG. Extrapyramidal reaction caused by ondansetron. Ann Pharmacother 1996 Feb; 30: 196
170. Jacobsen MB. Ondansetron in carcinoid syndrome [letter]. Lancet 1992 Jul 18; 340: 185
171. Sargent AI, Deppe SA, Chan FA. Seizure associated with ondansetron. Clin Pharm 1993 Aug; 12: 613-5
172. Mitchell KE, Popkin MK, Trick W, et al. Psychiatric complications associated with ondansetron. Psychosomatics 1994 Mar-Apr; 35: 161-3
173. Oren DA. Dysphoria after treatment with ondansetron [letter]. Am J Psychiatry 1995 Jul; 152: 1101
174. Chen M, Tanner A, Gallo-Torres H. Anaphylactoid-anaphylactic reactions associated with ondansetron [letter]. Ann Intern Med 1993 Oct 15; 119: 862
175. Madera J, Sanz S, Pérez CI, et al. Urticaria and angioedema caused by ondansetrom. Allergy 1995; 50 Suppl. 26: 214
176. Kossey JL, Kwok KK. Anaphylactoid reactions associated with ondansetron. Ann Pharmacother 1994 Sep; 28: 1029-30
177. Verrill M, Judson I. Jaundice with ondansetron. Lancet 1994 Jul 16; 344: 190-1
178. Heyman JS, Young ML, Bagshaw RJ, et al. Cardiovascular stability with rapid intravenous infusion of ondansetron. Can J Anaesth 1993 May; 40 (Pt 1): 448-52
179. Rose JB, McCloskey JJ. Rapid intravenous administration of ondansetron or metoclopramide is not associated with cardiovascular compromise in children. Paediatr Anaesth 1995; 5 (2): 121-4
180. Johnson BA, Rue J, Cowen PJ. Ondansetron and alcohol pharmacokinetics. Psychopharmacology 1993 Aug; 112: 145
181. 3 receptor antagonist ondansetron [abstract]. FASEB J 1993 Feb 23; 7 (Pt II): A699
182. Sullivan CA, Johnson CA, Roach H, et al. A prospective, randomized, double-blind comparison of the serotonin antagonist ondansetron to a standardized regimen of promethazine for hyperemesis gravidarum. A preliminary investigation [abstract]. Am J Obstet Gynecol 1995 Jan; 172 (Pt 2): 299
183. World MJ. Ondansetron and hyperemesis gravidarum [letter]. Lancet 1993 Jan 16; 341: 185
184. 3 antagonist in irritable bowel syndrome [abstract]. Gastroenterology 1991 May: 100 (Pt 2) Suppl.: A468
185. Schwörer H, Ramadori G. Improvement of cholestatic pruritus by ondansetron. Lancet 1993 May 15; 341: 1277